Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (currently amended) A compound of formula (I):



(I)

in which:

X is N ~~or NH~~;

Y is :CH, CO, CH_2 or :CNR^2R^3, where R^2 and R^3 are independently hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

R is aryl or heteroaryl optionally substituted by halogen, amino, hydroxy, cyano, nitro, trifluoromethyl, carboxy, $CONR^5R^6$, $SO_2NR^5R^6$, SO_2R^4, $NHSO_2R^4$, $NHCOR^4$, ethylenedioxy, methylenedioxy, C_{1-6} alkyl, C_{1-6} alkoxy, SR^4 or NR^5R^6 where R4 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl, R^5 and R^6 are independently hydrogen, C_{1-6} alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^4 group;

or R is C_{1-6} alkyl or C_{3-6} cycloalkyl,

R^1 is a group $Y(CH_2)pR^7$ where p is 0, 1 or 2 and Y is O or NR^8 where R^8 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

and R^7 is a 5- or 6-membered saturated ring containing one or more O, S or N atoms, aryl or a heteroaryl group containing one to four heteroatoms selected from O, S or N, the saturated ring, aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, trifluoromethyl, carboxy, $CONR^5R^6$, $SO_2NR^5R^6$, SO_2R^4, $NHSO_2R^4$, $NHCOR^4$, C_{1-6} alkyl, C_{1-6} alkoxy, SR^4 or NR^5R^6 where R4 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl, R^5 and R^6 are independently hydrogen, C_{1-6} alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^4 group;

or R^1 is a group NR^9R^{10} where R^9 and R^{10} are independently hydrogen or C_{1-6} alkyl, or R^9 and R^{10} together with the nitrogen atom to which they are attached form a 5 or 6-membered saturated ring optionally containing a further O, S or N atom and optionally substituted by a second NR^9R^{10} where R^9 and R^{10} are independently hydrogen or C_{1-6} alkyl or R^9 and R^{10} together with the nitrogen atom to which they are attached form a 5 or 6-membered saturated ring optionally containing a further O, S or NR^4, CO_2C_{1-6} alkyl, $CONR^{11}R^{12}$ where R^{11} and R^{12} are independently hydrogen or C_{1-6} alkyl, aryl or heteroaryl group optionally substituted by halogen, amino, hydroxy, cyano, nitro, trifluoromethyl, carboxy, $CONR^5R^6$, $SO_2NR^5R^6$, SO_2R^4, $NHSO_2R^4$, $NHCOR^4$, C_{1-6} alkyl, C_{1-6} alkoxy, SR^4 or NR^5R^6 where R4 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl, R^5 and R^6 are independently hydrogen, C_{1-6} alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^4 group;
and pharmaceutically acceptable salts or solvates thereof.

Claim 2. (previously presented) A compound according to claim 1 in which X is N and Y is :CH.

Claim 3. (previously presented) A compound according to claim 1, wherein R is C_{1-4}alkyl, or phenyl substituted by halogen, SO_2Me, C_{1-6}alkoxy or C_{1-4}alkyl.

Claim 4. (previously presented) A compound according to claim 1, wherein R^1 is a group $Y(CH_2)pR^7$ where p is 0 and Y is NR^8 where R^8 is hydrogen and R^7 is substituted phenyl.

Claim 5. (previously presented) A compound according to claim 1, wherein R^1 is NR^9R^{10} where R^9 and R^{10} are hydrogen or C_{1-3} alkyl or together with the nitrogen atom to which they are attached form a 5 or 6-membered saturated ring optionally containing a further O, S or NR^4.

Claim 6. (previously presented) A compound selected from:

1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide,

9-(4-Chlorophenyl)-6-(4-pyrrolidin-1-ylpiperidin-1-yl)-9H-purine-2-carbonitrile,

9-(4-Chlorophenyl)-6-[(3-pyrrolidin-1-ylpropyl)amino]-9H-purine-2-carbonitrile,

6-(4-Aminopiperidin-1-yl)-9-(4-chlorophenyl)-9H-purine-2-carbonitrile,

6-[(2-Aminoethyl)amino]-9-(4-chlorophenyl)-9H-purine-2-carbonitrile,

9-(4-Chlorophenyl)-6-(dimethylamino)-9H-purine-2-carbonitrile,

9-(4-Methylphenyl)-6-pyrrolidin-1-yl-9H-purine-2-carbonitrile,

9-(4-Methoxyphenyl)-6-pyrrolidin-1-yl-9H-purine-2-carbonitrile,

9-(4-chlorophenyl)-6-pyrrolidin-1-yl-9H-purine-2-carbonitrile,

9-(4-Chlorophenyl)-6-(ethylamino)-9H-purine-2-carbonitrile,

tert-Butyl 4-[9-(4-chlorophenyl)-2-cyano-9H-purin-6-yl]piperazine-1-carboxylate,

9-(4-Chlorophenyl)-6-piperazin-1-yl-9H-purine-2-carbonitrile,

9-(2-Chlorophenyl)-6-morpholin-4-yl-9H-purine-2-carbonitrile

9-(3,4-Difluorophenyl)-6-morpholin-4-yl-9H-purine-2-carbonitrile,

9-(4-Isopropylphenyl)-6-morpholin-4-yl-9H-purine-2-carbonitrile,

9-(4-Methoxyphenyl)-6-morpholin-4-yl-9H-purine-2-carbonitrile,

9-(3-Chlorophenyl)-6-morpholin-4-yl-9H-purine-2-carbonitrile,

9-[4-(Methylsulfonyl)phenyl]-6-morpholin-4-yl-9H-purine-2-carbonitrile,

6-[(4-Chlorophenyl)amino]-9-ethyl-9H-purine-2-carbonitrile,

9-(4-Chlorophenyl)-6-morpholin-4-yl-9H-purine-2-carbonitrile,

8-Amino-6-[(4-chlorophenyl)amino]-9-ethyl-9H-purine-2-carbonitrile,

8-Amino-9-(4-chlorophenyl)-6-morpholin-4-yl-9H-purine-2-carbonitrile,

9-(4-Chlorophenyl)-6-morpholin-4-yl-8-oxo-8,9-dihydro-7H-purine-2-carbonitrile,

9-(4-Chlorophenyl)-8-(dimethylamino)-6-morpholin-4-yl-9H-purine-2-carbonitrile,

and pharmaceutically acceptable salts thereof.

Claim 7. (cancelled)

Claim 8. (cancelled)

Claim 9. (cancelled)

Claim 10. (previously presented) A pharmaceutical composition which comprises a compound of the formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

Claim 11. (previously presented) A method for producing inhibition of at least one cysteine protease chosen from cathepsins S, K, L , F and B in a mammal comprising administering to said mammal an effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.

Claim 12. (previously presented) A method for treating pain in a mammal in need of such treatment comprising administering to said mammal an effective amount of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.

Claim 13. (previously presented) A method for inhibiting Cathepsin S in a warm blooded animal comprising administering a compound of the formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof to a warm blooded animal.

Claim 14. (previously presented) A pharmaceutical composition which comprises a compound of the formula (I) as defined in claim 6 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

Claim 15. (previously presented) A method for producing inhibition of at least one cysteine protease chosen from cathepsins S, K, L, F and B in a mammal comprising administering to said mammal an effective amount of a compound as defined in claim 6, or a pharmaceutically acceptable salt thereof.

Claim 16. (previously presented) A method for treating pain in a mammal in need of such treatment comprising administering to said mammal an effective amount of a compound as defined in claim 6, or a pharmaceutically acceptable salt thereof.

Claim 17. (previously presented) A method for inhibiting Cathepsin S in a warm blooded animal comprising administering a compound of the formula (I) as defined in claim 6 or a pharmaceutically acceptable salt thereof to a warm blooded animal.